Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Dermatology

Monitoring and Long-Term Outlook

At a Glance

The long-term outlook for bullous pemphigoid depends heavily on holistic care. The primary risks often stem from steroid treatment side effects and pre-existing conditions, rather than the skin disease itself. Relapses are common, making daily symptom monitoring essential for long-term health.

Managing Bullous Pemphigoid (BP) is a marathon, not a sprint. Long-term care focuses on maintaining clear skin while protecting your body from the side effects of treatment and the complications of aging.

Understanding the Outlook

It is important to be direct about the prognosis for BP, especially for elderly patients. While BP is a serious condition, it is vital to understand that severe complications are rarely caused by the skin disease itself. Instead, the main risks are driven by:

  • Pre-existing Health Conditions: Many patients already manage serious issues like heart disease, diabetes, or neurological disorders [1][2].
  • Treatment Side Effects: High-dose systemic steroids (like prednisone) can weaken the immune system, making it harder to fight off common infections [3][4].

Because of this, the most successful care plans are holistic, meaning they focus on the whole person, not just the skin [2][5].

Monitoring for Relapse

Relapse—where the disease returns after being under control—is common in BP, occurring in 20% to 60% of patients [6][7].

  • Early Warning Signs: A relapse often starts with intense itching or red, hive-like patches before any blisters appear [8].
  • Predictors: Patients who start with very high levels of anti-BP180 antibodies or high levels of eosinophils in their blood may have a higher risk of the disease coming back [9][10].

Daily Surveillance Checklist

Caregivers and patients should perform a brief “check-in” every day to catch potential issues early.

What to Monitor Why It Matters Warning Signs
New Blisters/Itch Tracks disease activity Any new tense blisters or a return of severe itching [11].
Signs of Infection Steroids hide infection signs Fever, confusion, redness/pus at blister sites, or a new cough [12][5].
Blood Sugar Steroids can cause diabetes Frequent thirst, blurred vision, or high readings on a glucose monitor [13].
Blood Pressure Steroids can raise pressure Sudden headaches, dizziness, or readings higher than your “normal” [13].
Bone and Joint Pain Steroids cause bone density loss (osteoporosis) New back/hip pain. Ask your doctor about calcium/Vitamin D and bone scans [13].
Vision Changes Steroids increase eye risks Blurry vision or halos. Regular eye exams for cataracts/glaucoma are needed [13].
Mood/Memory Links to BP & Steroids Increased confusion, sadness, or extreme restlessness [14][4].

Recommended Follow-Up Schedule

While your doctor will tailor a plan for you, a standard monitoring schedule often includes:

  1. Active Phase (Weeks 1-4): Weekly or bi-weekly visits to check blister counts and adjust medication doses [15].
  2. Tapering Phase (Months 2-6): Monthly visits with blood work to monitor glucose, kidney function, and electrolytes [16].
  3. Maintenance/Remission (6+ Months): Visits every 3-6 months to ensure the disease remains quiet and to continue slowly reducing medications [17].

By staying vigilant and maintaining a close relationship with your dermatology team, you can manage the risks and focus on a better quality of life [18].

Common questions in this guide

What is the long-term outlook for someone with bullous pemphigoid?
While bullous pemphigoid is a serious condition, severe complications rarely come from the skin disease itself. The primary long-term risks are typically driven by pre-existing health issues and side effects from strong medications like high-dose steroids.
What are the early warning signs that bullous pemphigoid is coming back?
A relapse often begins with intense itching or red, hive-like patches on the skin, which can happen before any new blisters appear. Relapses are very common, occurring in 20% to 60% of patients.
What should I monitor daily while being treated for bullous pemphigoid?
You and your caregiver should check daily for new blisters, increased itching, and any signs of infection. Because of steroid treatments, it is also important to track your blood sugar, blood pressure, mood changes, and any new bone or joint pain.
Why do I need bone density scans and eye exams if I only have a skin condition?
The high-dose systemic steroids often used to clear your skin can cause side effects throughout your entire body. These medications can cause bone density loss (osteoporosis) and increase the risk of eye conditions like cataracts and glaucoma, making regular full-body monitoring essential.
How often will I need to see my dermatologist once my skin clears?
During the active blistering phase, you may need weekly or bi-weekly visits. Once your disease is quiet and you enter remission, visits are typically spaced out to every 3 to 6 months to monitor for relapse and safely reduce your medications.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my age and other health conditions, what are the most critical risks I face while on this treatment?
  2. 2.What is our specific plan for tapering down my steroid dose, and what 'warning signs' should I look for during the taper?
  3. 3.Do you recommend starting a calcium and Vitamin D supplement, or getting a bone density scan, to protect my bones from steroid side effects?
  4. 4.If I have a history of heart disease or stroke, how will that affect the way we manage my BP?
  5. 5.What specific symptoms should trigger an emergency call to your office rather than waiting for my next appointment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Prognostic factors for mortality in bullous pemphigoid: A systematic review and meta-analysis.

    Chen X, Zhang Y, Luo Z, et al.

    PloS one 2022; (17(4)):e0264705 doi:10.1371/journal.pone.0264705.

    PMID: 35427358
  2. 2

    Bullous pemphigoid.

    Miyamoto D, Santi CG, Aoki V, Maruta CW

    Anais brasileiros de dermatologia 2019; (94(2)):133-146 doi:10.1590/abd1806-4841.20199007.

    PMID: 31090818
  3. 3

    Association of bullous pemphigoid and comorbid health conditions: a case-control study.

    Lee S, Rastogi S, Hsu DY, et al.

    Archives of dermatological research 2021; (313(5)):327-332 doi:10.1007/s00403-020-02100-2.

    PMID: 32647978
  4. 4

    The Association Between Bullous Pemphigoid and Neurological Disorders in A Selected Malaysian Population.

    Kwan Z, Lai YN, Ch'ng CC, et al.

    The Medical journal of Malaysia 2015; (70(2)):81-5.

    PMID: 26162382
  5. 5

    Survival and prognostic factors in bullous pemphigoid: A retrospective cohort study.

    Papara C, Chiorean R, Leucuta DC, et al.

    Indian journal of dermatology, venereology and leprology 2023; (89(3)):363-371.

    PMID: 36331841
  6. 6

    Evaluation of Dupilumab in Patients With Bullous Pemphigoid.

    Zhao L, Wang Q, Liang G, et al.

    JAMA dermatology 2023; (159(9)):953-960 doi:10.1001/jamadermatol.2023.2428.

    PMID: 37531116
  7. 7

    Risk factors predisposing relapse of bullous pemphigoid at initial diagnosis: A retrospective cohort study of 205 patients.

    Liu Y, Wang Y, Zhang J, et al.

    International immunopharmacology 2023; (125(Pt A)):111082 doi:10.1016/j.intimp.2023.111082.

    PMID: 37913571
  8. 8

    Phototherapy with UVB-NB as a new adjuvant therapy for bullous pemphigoid: A pilot study.

    Vassallo C, Pellico MR, Gherzi S, et al.

    Photodermatology, photoimmunology & photomedicine 2022; (38(2)):169-172 doi:10.1111/phpp.12722.

    PMID: 34351011
  9. 9

    High Index Values of Enzyme-Linked Immunosorbent Assay for BP180 at Baseline Predict Relapse in Patients With Bullous Pemphigoid.

    Koga H, Teye K, Ishii N, et al.

    Frontiers in medicine 2018; (5()):139 doi:10.3389/fmed.2018.00139.

    PMID: 29868591
  10. 10

    Association of Peripheral Blood and Cutaneous Eosinophils With Bullous Pemphigoid Disease Severity and Treatment Outcomes.

    Garrido PM, Aguado-Lobo M, Espinosa-Lara P, et al.

    Actas dermo-sifiliograficas 2022; (113(9)):T881-T887 doi:10.1016/j.ad.2022.05.025.

    PMID: 36055383
  11. 11

    Actigraphy-measured nocturnal wrist movements and assessment of sleep quality in patients with bullous pemphigoid: a pilot case-control study.

    Kalinska-Bienias A, Piotrowski T, Kowalczyk E, et al.

    Clinical and experimental dermatology 2019; (44(7)):759-765 doi:10.1111/ced.13902.

    PMID: 30652344
  12. 12

    Assessment of the Characteristics and Associated Factors of Infectious Complications in Bullous Pemphigoid.

    Chen J, Mao X, Zhao W, et al.

    Frontiers in immunology 2020; (11()):1607 doi:10.3389/fimmu.2020.01607.

    PMID: 32793235
  13. 13

    An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone.

    Sticherling M, Franke A, Aberer E, et al.

    The British journal of dermatology 2017; (177(5)):1299-1305 doi:10.1111/bjd.15649.

    PMID: 28494097
  14. 14

    Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).

    Borradori L, Van Beek N, Feliciani C, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2022; (36(10)):1689-1704 doi:10.1111/jdv.18220.

    PMID: 35766904
  15. 15

    International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid.

    Masmoudi W, Vaillant M, Vassileva S, et al.

    The British journal of dermatology 2021; (184(6)):1106-1112 doi:10.1111/bjd.19611.

    PMID: 33067805
  16. 16

    Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy.

    Montagnon CM, Lehman JS, Murrell DF, et al.

    Journal of the American Academy of Dermatology 2021; (85(1)):18-27 doi:10.1016/j.jaad.2020.05.161.

    PMID: 33684494
  17. 17

    Bullous Pemphigoid and Other Pemphigoid Dermatoses.

    Pratasava V, Sahni VN, Suresh A, et al.

    Medicina (Kaunas, Lithuania) 2021; (57(10)) doi:10.3390/medicina57101061.

    PMID: 34684098
  18. 18

    Depression and Anxiety in Patients with Bullous Pemphigoid: Impact and Management Challenges.

    Kluger N, Pankakoski A, Panelius J

    Clinical, cosmetic and investigational dermatology 2020; (13()):73-76 doi:10.2147/CCID.S212984.

    PMID: 32021371

This page provides educational information on long-term monitoring for bullous pemphigoid. Always consult your dermatologist to tailor a follow-up schedule and safely manage treatment side effects.

Get notified when new evidence is published on Bullous pemphigoid.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.